Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Veracyte (VCYT) Accumulated Expenses (2016 - 2025)

Historic Accumulated Expenses for Veracyte (VCYT) over the last 14 years, with Q3 2025 value amounting to $48.4 million.

  • Veracyte's Accumulated Expenses rose 1025.94% to $48.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $48.4 million, marking a year-over-year increase of 1025.94%. This contributed to the annual value of $43.8 million for FY2024, which is 1405.0% up from last year.
  • Veracyte's Accumulated Expenses amounted to $48.4 million in Q3 2025, which was up 1025.94% from $43.7 million recorded in Q2 2025.
  • Veracyte's 5-year Accumulated Expenses high stood at $48.4 million for Q3 2025, and its period low was $16.3 million during Q1 2021.
  • In the last 5 years, Veracyte's Accumulated Expenses had a median value of $35.9 million in 2025 and averaged $35.5 million.
  • Per our database at Business Quant, Veracyte's Accumulated Expenses soared by 23724.9% in 2021 and then tumbled by 2050.18% in 2023.
  • Veracyte's Accumulated Expenses (Quarter) stood at $39.5 million in 2021, then dropped by 4.31% to $37.8 million in 2022, then increased by 1.73% to $38.4 million in 2023, then rose by 14.05% to $43.8 million in 2024, then rose by 10.38% to $48.4 million in 2025.
  • Its Accumulated Expenses stands at $48.4 million for Q3 2025, versus $43.7 million for Q2 2025 and $35.9 million for Q1 2025.